Lets break it down properly First: The medical difference(This is the core) IBD: Inflammatory Bowel Disease A chronic autoimmune inflammatory condition Includes Crohns disease & Ulcerative colitis Structural damage to the gut (ulcers, strictures, fistulas) Diagnosed via endoscopy, imaging, labs, biopsies** Can lead to complications if untreated IBS: Irritable Bowel Syndrome A functional gut disorder No structural damage or inflammation Diagnosis of exclusion (normal scopes & labs) Symptoms are real, pathology is not visible Key takeaway: IBD = inflammation & tissue damage IBS = gutbrain interaction dysfunction Signs & Symptoms (How they present differently) IBD Chronic diarrhea (often nocturnal) Blood and/or mucus in stool Weight loss Fatigue Anemia Fever during flares Extra-intestinal symptoms (joints, skin, eyes) IBS Abdominal pain relieved by defecation Bloating and gas Constipation, diarrhea, or mixed pattern Symptoms fluctuate with stress & food No bleeding, no weight loss, no anemia Red flags = think IBD, not IBS Medical Nutrition Therapy (Where confusion often happens) Nutrition in IBD Supportive but critical Goals change based on: Disease activity (flare vs remission) Location of disease Nutritional status Focus on: Preventing malnutrition Correcting deficiencies (iron, B12, vitamin D, zinc) Reducing symptom burden during flares Sometimes requires: Enteral nutrition Temporary food modifications Close MDT collaboration Nutrition in IBS Primary treatment pillar Highly symptom-driven Focus on: Identifying triggers Gutbrain axis modulation Common approaches: Low FODMAP (structured, time-limited) Meal timing & regularity Fiber type adjustment Long-term goal: food freedom, not restriction Is the Approach Individualized
A comprehensive medical history review is standard prior to treatment initiation to screen for contraindications or potential risks
It plays an important role in cellular repair and energy metabolism
Is your diet lacking sulfur
ZS: Conceptualization, Project administration, Resources, Supervision, Writing review & editing
Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist
